Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Song, J. H.
Right arrow Articles by Hao, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Song, J. H.
Right arrow Articles by Hao, C.
Clinical Cancer Research Vol. 9, 4255-4266, September 15, 2003
© 2003 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Cisplatin Down-Regulation of Cellular Fas-associated Death Domain-like Interleukin-1ß-converting Enzyme-like Inhibitory Proteins to Restore Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Melanoma Cells1

Jin H. Song, Doyoun K. Song, Meenhard Herlyn, Kenneth C. Petruk and Chunhai Hao2

Departments of Laboratory Medicine and Pathology [J. H. S., D. K. S., C. H.], and Surgery [K. C. P.], University of Alberta, Edmonton, Alberta, Canada T6G 2S2, and The Wistar Institute, Philadelphia, Pennsylvania 19104 [M. H.]

Purpose: Many melanoma cell lines and primary cultures are resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. In this study, we investigated the molecular mechanisms that control melanoma cell resistance and searched for chemotherapeutic drugs that could overcome the TRAIL resistance in melanoma cells.

Experimental Design: We examined 21 melanoma cell lines and 3 primary melanoma cultures for their sensitivity to TRAIL-induced apoptosis, and then tested cisplatin, chemptothecin, and etoposide for their synergistic effects on TRAIL sensitivity in resistant melanoma cells.

Results: Of 21 melanoma cell lines, 11 showed various degrees of sensitivity to TRAIL-induced apoptosis through caspase-8-initiated cleavage of caspase-3 and DNA fragmentation factor 45. The remaining cell lines and primary cultures were resistant to TRAIL, but cisplatin, chemptothecin, and etoposide sensitized the resistant cell lines and primary cultures to TRAIL-induced apoptosis, which also occurred through the caspase-8-initiated caspase cascade. Of the two TRAIL death receptors (DR4 and DR5), melanoma cells primarily expressed DR5 on cell surface. Cisplatin treatment had no effects on cell surface DR5 expression or intracellular expression of Fas-associated death domain and caspase-8. Instead, cisplatin treatment down-regulated intracellular expression of the short form of cellular Fas-associated death domain-like interleukin-1ß-converting enzyme-like inhibitory protein (c-FLIP) and inhibited phosphorylation of the long form of c-FLIP.

Conclusions: The results presented here indicate that cisplatin inhibits c-FLIP protein expression and phosphorylation to restore TRAIL-induced caspase-8-initiated apoptosis in melanoma cells, thus providing a new combined therapeutic strategy for melanomas.




This article has been cited by other articles:


Home page
Cancer Res.Home page
J. H. Song, M. C.L. Tse, A. Bellail, S. Phuphanich, F. Khuri, N. M. Kneteman, and C. Hao
Lipid Rafts and Nonrafts Mediate Tumor Necrosis Factor Related Apoptosis-Inducing Ligand Induced Apoptotic and Nonapoptotic Signals in Non Small Cell Lung Carcinoma Cells
Cancer Res., July 15, 2007; 67(14): 6946 - 6955.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Y. Chen, J. Xu, N. Jhala, P. Pawar, Z. B. Zhu, L. Ma, C.-H. Byon, and J. M. McDonald
Fas-Mediated Apoptosis in Cholangiocarcinoma Cells Is Enhanced by 3,3'-Diindolylmethane through Inhibition of AKT Signaling and FLICE-Like Inhibitory Protein
Am. J. Pathol., November 1, 2006; 169(5): 1833 - 1842.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. H. Song, A. Bellail, M. C. L. Tse, V. W. Yong, and C. Hao
Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
J. Neurosci., March 22, 2006; 26(12): 3299 - 3308.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Poukkula, A. Kaunisto, V. Hietakangas, K. Denessiouk, T. Katajamaki, M. S. Johnson, L. Sistonen, and J. E. Eriksson
Rapid Turnover of c-FLIPshort Is Determined by Its Unique C-terminal Tail
J. Biol. Chem., July 22, 2005; 280(29): 27345 - 27355.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. C. Broaddus, T. B. Dansen, K. S. Abayasiriwardana, S. M. Wilson, A. J. Finch, L. B. Swigart, A. E. Hunt, and G. I. Evan
Bid Mediates Apoptotic Synergy between Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and DNA Damage
J. Biol. Chem., April 1, 2005; 280(13): 12486 - 12493.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.